<DOC>
	<DOCNO>NCT00002263</DOCNO>
	<brief_summary>To assess safety efficacy subcutaneous sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) increase maintain granulocyte count HIV-infected child develop granulocytopenia result continuous intravenous ( CIV ) zidovudine ( AZT ) . To assess short-term long-term effect concomitant GM-CSF hematologic parameter . To assess potential therapeutic benefit concomitant GM-CSF AZT natural history HIV infection associate infectious complication .</brief_summary>
	<brief_title>A Pilot Study Evaluate Effects Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor Pediatric HIV-Infected Patients With Neutropenia Secondary Azidothymidine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) NIAID 86C175 . Patients must : Diagnosis perinatal transfusion acquire AIDS AIDS relate complex . Granulocytopenia ( &lt; = 800 cells/mm3 ) associate administration AZT protocol NIAID 86C175 . Life expectancy &gt; 3 month . Functioning indwell central venous access device place . Prior Medication : Allowed within 48 hour study entry : Prophylactic antibiotic . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Critically ill clinically unstable . Significant , active opportunistic infection require specific drug therapy time study entry . Ongoing IV alimentation . Uncorrected nutritional deficiency may contribute anemia and/or leukopenia . Past history current evidence chronic hematologic disorder hemophilia A B , anemia chronic disease anemia relate HIV infection . Malignancy likely require systemic treatment study . Patients follow exclude : Critically ill , clinically unstable , concomitant disease list Patient Exclusion Coexisting Conditions . Hypersensitivity zidovudine ( AZT ) nucleoside analog . Prior Medication : Excluded within 48 hour study entry : Antibiotics . Excluded within 30 day study entry : Antiretroviral agent zidovudine ( AZT ) . Acyclovir . Ganciclovir . Any investigational drug . Immunomodulating drug . Cytolytic chemotherapeutic agent . Corticosteroids . Immunoglobulin preparation . Excluded within 4 month study entry : Suramin . Prior Treatment : Excluded within 6 month study entry : Bone marrow transplantation . Excluded within 4 week study entry : Lymphocyte transfusion . Radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 1990</verification_date>
	<keyword>Pilot Projects</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>